论文部分内容阅读
许多抗生素类药物都可引起皮肤不良反应,研究者们在吉米沙星的初期临床研究中也观察到了此迹象。随后进行的研究及分析结果均表明,吉米沙星引发的皮肤反应为轻、中度自限性斑丘疹,并且最常见于疗程>7 d(非批准疗程)的患者。采用5 d和7 d疗程分别治疗慢性支气管炎急性发作(AECB)和社区获得性肺炎(CAP)时,吉米沙星引起的药疹发生率与其他氟喹诺酮类药物相当,而且低于其他常用于社区感染的抗生素类药物,如甲氧苄啶-磺胺甲噁唑和头孢类抗生素。与吉米沙星治疗相关的药疹无交叉或亚临床致敏作用,也不会引起任何系统性疾病,如Stevens-Johnson综合征或中毒性表皮坏死症等。本文对吉米沙星的临床研究进行了综述,为本品短程疗法对付AECB和CAP提供佐证。
Many antibiotic drugs can cause adverse skin reactions, researchers have also observed this sign in the initial clinical study of gemifloxacin. Subsequent studies and analyzes showed that the skin reaction induced by gemifloxacin was mild and moderately self-limiting rash and most commonly found in patients who were> 7 d (non-approved). The rates of drug eruption caused by gemifloxacin were comparable to those of other fluoroquinolones at 5 and 7 days of treatment for acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumonia (CAP), respectively, and were lower than those commonly used in the community Infected antibiotics such as trimethoprim-sulfamethoxazole and cephalosporins. Drugs associated with gemifloxacin therapy have no cross or subclinical sensitization and do not cause any systemic disease such as Stevens-Johnson syndrome or toxic epidermal necrosis. This article summarizes the clinical research of gemifloxacin and provides evidence for the treatment of AECB and CAP by this short-term therapy.